MOSCOW (MRC) -- To ensure the energy supply to Marl Chemical Park, Evonik’s largest production facility, contracts were signed yesterday to build a new combined-cycle gas turbine (CCGT) power plant, according to the company's statement.
The plant is a joint project of Evonik and E.ON. Siemens will supply the CCGT.
Marl Chemical Park currently receives electricity and steam from three power plants consisting of a total of five generating units. The oldest of these is unit 3, which in a few years will reach the end of its useful operating life. Unit 3 will be replaced with a new CCGT plant with 60 megawatts (MW) of electric capacity. E.ON will build the new plant at a central location at Evonik’s production facility; the plant is expected to enter service in 2015. Switching from coal to gas will enable Evonik to reduce its carbon emissions at Marl by about 280,000 metric tons annually.
Evonik will control and have operational and legal responsibility for the power plant once it is in service. E.ON will plan, finance, and build the new Marl plant and provide a number of services related to its operation.
"The new CCGT will be an important step toward updating Marl Chemicals Park’s power and steam supply," said Caspar Gammelin, President Site Services at Evonik. "In view of E.ON’s well-earned reputation for new-build expertise, we’re pleased to have them as a partner in our joint project." The new plant will ensure that Marl Chemical Park has a reliable and cost-effective supply of power and heat well into the future.
As MRC wrote previously, Evonik is launching a new generation of PVC plasticizers under the ELATUR product brand. With this strategic portfolio expansion, Evonik is consistently developing its range of sustainable plasticizers. Plasticizers from Evonik are primarily used in the plastics, automotive, and construction industry.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. In 2012 Evonik generated sales of EUR13.6 billion and an operating result (adjusted EBITDA) of EUR2.6 billion.
MRC